DermDocs LivDerm

n support of Eczema Awareness Month, LiVDerm sat down with one of the nation’s top experts on atopic dermatitis, Christopher G. Bunick, MD, PhD, to discuss this widespread skin condition that affects millions worldwide.
 
Associate professor of dermatology at Yale University School of Medicine, Dr. Bunick covers emerging targeted therapies and also looks at the concerns over their safety and efficacy. He also addresses some of the gaps that persist in treatment despite these new therapies. 

In support of Eczema Awareness Month, LiVDerm sat down with one of the nation’s top experts on atopic dermatitis, Peter A. Lio, MD, to discuss this widespread skin condition that affects millions worldwide.
 
Dr. Lio, a clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine, focuses on caring for pediatric patients with eczema in his interview. He provides unique insight into how best to combine integrative and pharmacologic treatments. 

Natasha A. Mesinkovska, MD, PhD, who spoke on the live satellite symposium "Gamechangers in Alopecia Areata" at the SBS 2023 meeting, speaks out about comorbid conditions often seen in alopecia areata patients, as well as her personal approach to treatment.
Questions:
We’ve heard a lot about comorbid conditions often seen in patients with alopecia areata. Do you have any pearls you’d like to share regarding screening or multidisciplinary care for patients with comorbidities?
What is your personal approach to developing a treatment plan for your patients with alopecia areata? 
Thank you for your time today, Dr Mesinkovska. This was very informative. Is there anything else you’d like to add?
 
Date: February 10, 2023

Brett King, MD, PhD, who spoke on the live satellite symposium "Gamechangers in Alopecia Areata" at the SBS 2023 meeting, speaks out about the rising use of JAK inhibitors to treat patients with alopecia areata.
Questions:
JAK inhibitors are taking the dermatology field by storm, with several approvals for multiple dermatologic conditions over the past couple of years. What is it that makes JAK inhibitors a gamechanger for treatment of alopecia areata?
In 2022, the first ever targeted treatment for alopecia areata, baricitinib, was approved by the FDA for adult patients. What additional treatments or FDA approvals can we expect to see in 2023?
Thank you for your time today, Dr King. This was fantastic. Is there anything else you’d like to add?
 
Date: February 10, 2023

Brittany Craiglow, MD, who spoke on the live satellite symposium "Gamechangers in Alopecia Areata" at the SBS 2023 meeting, shares her personal approach to treating pediatric patients with alopecia areata.
Questions:
What is your personal approach to developing a treatment plan with your patients and/or their caregivers? Do find yourself utilizing shared decision-making or other nuances to communicating with patients and caregivers?
You mainly treat pediatric and adolescent patients for hair loss in your clinical practice. Are there any specific nuances you’d like to share in regard to treating pediatric versus adult patients suffering from hair loss?
Thank you for your time today, Dr Craiglow. This was wonderful. Is there anything else you’d like to add?
 
Recorded Date: February 10, 2023

Elaine Siegfried, MD, who spoke on the live satellite symposium "Infants and Atopic Dermatitis" at the MOPD 2023 meeting, shares her expert advice for formulating a treatment plan and incorporating newer treatment options when managing pediatric patients with atopic dermatitis.
Questions:
With recently expanded age indications for therapeutic agents to treat pediatric AD, what steps should clinicians consider when formulating a treatment plan for their younger patients? The treatment landscape for atopic dermatitis in pediatric patients has shown much growth over the past couple of years. How do you foresee the treatment landscape continuing to change in 2023? This was excellent, Dr Siegfried, thank you for your time. Is there anything else you’d like to add?  
Date: February 10, 2023